• UTI
  • Septicemia, including serious central nervous system infections (use in combination)
  • Lower respiratory tract infections (use in combination)
  • Complicated urinary tract infections
  • Intra-abdominal infections, including peritonitis (use in combination)
  • Skin, bone, and skin structure infections (use in combination)
  • Management of cystic fibrosis with P. aeruginosa (as tobramycin inhalation)
    • Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in less than one second (FEV1) less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.
  • Treatment of ocular infections (uncomplicated conjunctivitis-ophthalmic solution)


  • Pneumonia, hospital-acquired (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, or a third-/fourth-generation cephalosporin)
    • Considered in patients with MDR gram negative infections.
    • Efficacy is unproven.
  • Pseudomonal infections (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, carbapenem or a third/fourth-generation cephalosporin)
  • Bronchiectasis, non-cystic fibrosis (inhaled)
  • Otitis external (tobramycin/dexamethasone topical)

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 16, 2023